New Chemical Entities with improved safety, efficacy, dosing, and cost-effectiveness

Development Pipeline

Programs

Description

Discovery

Pre-Clinical

IND

Phase 1

GM-1020: Oral NMDAR Antagonist
Orally Bioavailable, Rapid-acting, Fewer Dissociative Effects, Indications: Depression and Others
Non-hallucinogenic, Abuse-deterrent, Improved Cardiac Safety Profile, Indications: Depression and Others
Improved Cardiac Safety Profile, Improved Efficacy, Indications: Opioid Abuse Disorder and others
Rapid-acting, Cost-effective, Improved Cardiac Safety Profile, Indications: Depression and Others
GM-200X: 5-HT2AR Non-Hallucinogenic
GM-2505: 5-HT2A Agonist/5-HT Releaser
GM-300X: Safer Ibogaine Analogs

Program

GM-1020: Oral NMDAR Antagonist

Description

Orally Bioavailable, Rapid-acting, Fewer Dissociative Effects, Indications: Depression and Others

Phase

IND
Discovery | Pre-Clinical | IND Phase 1

Program

GM-2505: 5-HT2AR Short Acting Reset

Description

Rapid-acting, Cost-effective, Improved Cardiac Safety Profile, Indications: Depression and Others

Phase

IND
Discovery | Pre-Clinical | IND Phase 1

Program

GM-200X: 5-HT2AR Non-Hallucinogenic

Description

Orally Bioavailable, Rapid-acting, Fewer Dissociative Effects, Indications: Depression and Others

Phase

Pre-clinical
Discovery | Pre-Clinical | IND Phase 1

Program

GM-300X: Safer Ibogaine Analogs

Description

Improved Cardiac Safety Profile, Improved Efficacy, Indications: Opioid Abuse Disorder and others

Phase

Pre-clinical
Discovery | Pre-Clinical | IND Phase 1
Gilgamesh Pharmaceuticals
113 University Place, Suite 1019, NY, NY 10003
info@gilgameshpharmaceutical.com